Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroendocrine tumours.

M T Barakat1, K Meeran, S R Bloom

  • 1Department of Metabolic Medicine, Division of Investigative Science, Imperial College London at Hammersmith Campus, Du Cane Road, London W12 ONN, UK.

Endocrine-Related Cancer
|March 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sheehan's like syndrome in a man.

QJM : monthly journal of the Association of Physicians·2019
Same author

Addisonian crisis: assessment and management.

British journal of hospital medicine (London, England : 2005)·2018
Same author

Using kisspeptin to assess GnRH function in an unusual case of primary amenorrhoea.

Endocrinology, diabetes & metabolism case reports·2017
Same author

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.

Journal of viral hepatitis·2015
Same author

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

Journal of viral hepatitis·2015
Same author

Strategies to manage hepatitis C virus infection disease burden - volume 3.

Journal of viral hepatitis·2015
Same journal

The Role of the B7 Family in Autoimmune Thyroid Diseases and Thyroid Cancer.

Endocrine-related cancer·2026
Same journal

Lineage-Specific Steroidomic Signatures in Pituitary Neuroendocrine Tumors: Pregnenolone Enrichment in SF-1 Lineage and Associations with Tumor Behavior.

Endocrine-related cancer·2026
Same journal

Characterization of SF3B1 role in prolactin-secreting pituitary tumors.

Endocrine-related cancer·2026
Same journal

The NET Score: An Interpretable AI-Assisted Prognostic Score for Mortality Risk in Lung Neuroendocrine Tumors.

Endocrine-related cancer·2026
Same journal

Intraprostatic steroid hormones and endocrine disruptors in prostate cancer.

Endocrine-related cancer·2026
Same journal

Functional Imaging in Hereditary Endocrine Neoplasms: Evolving Modalities and Clinical Implications.

Endocrine-related cancer·2026
See all related articles

Neuroendocrine tumors, a diverse group of cancers, are increasingly recognized for their hormonal effects and genetic links. Advances in diagnosis and treatments like somatostatin analogs offer improved patient outcomes.

Area of Science:

  • Endocrinology
  • Oncology
  • Genetics

Background:

  • Neuroendocrine tumors (NETs) are a heterogeneous group, including carcinoid, gastroenteropancreatic NETs, pituitary tumors, medullary thyroid carcinoma, and pheochromocytomas.
  • These tumors are notable for hormone production, leading to characteristic clinical effects, and have garnered significant research interest.
  • Understanding neuroendocrine cell phenotypes has evolved, defining them by specific cellular characteristics and functions.

Purpose of the Study:

  • To review the current understanding of neuroendocrine tumor diagnosis and management.
  • To evaluate therapeutic strategies for various NETs, including carcinoid and gastroenteropancreatic NETs.
  • To discuss the role of genetic factors and emerging treatments in managing these conditions.

Main Methods:

Related Experiment Videos

  • Review of existing literature on neuroendocrine tumors.
  • Evaluation of diagnostic tools, including neuroendocrine markers like chromogranin A.
  • Assessment of current and novel therapeutic approaches, such as somatostatin analogs and genetic screening.

Main Results:

  • Neuroendocrine markers, especially chromogranin A, are crucial for diagnosis.
  • Genetic screening aids in risk stratification and prevention of morbidity.
  • Pharmacological therapies, including somatostatin analogs, significantly improve symptom control and offer targeted treatment for metastatic disease.

Conclusions:

  • Neuroendocrine tumors require a multidisciplinary approach for effective management.
  • Advances in understanding tumor biology and genetics are paving the way for personalized treatment strategies.
  • Targeted therapies and improved diagnostic markers are enhancing patient outcomes and quality of life.